Agilent xcelligence rtca instrumentation applied in recent fda approval

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) is pleased to announce its role in supporting autolus therapeutics' fda approval for aucatzyl®, a recently approved car t therapy. agilent's advanced cell analysis instrumentation, specifically the xcelligence real-time cell analysis (rtca) technology, was applied in developing and validating aucatzyl. the xcelligence rtca technology supported the development and implementation of the potency assay. by providing precise a.
A Ratings Summary
A Quant Ranking